Lisdexamfetamine: Nursing Drug Guide, Abuse Risk & NCLEX Review

Vyvanse (lisdexamfetamine dimesylate) is the primary U.S. brand, available as capsules and chewable tablets for once-daily oral use. Generic lisdexamfetamine products may appear on the MAR. Because it is Schedule II, verify drug name, strength, formulation (capsule vs chewable), and controlled-substance count at every pass.

Capsule strengths include 10, 20, 30, 40, 50, 60, and 70 mg; chewable tablets include 10, 20, 30, 40, 50, and 60 mg per Vyvanse prescribing information.

Vyvanse is a CNS stimulant indicated for attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older, and for moderate to severe binge eating disorder (BED) in adults per FDA prescribing information. It is not indicated for weight loss; use of sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events.

↔On a small screen, swipe or scroll sideways to see the full table.

Lisdexamfetamine is a prodrug that is converted primarily to dextroamphetamine, which blocks norepinephrine and dopamine reuptake and increases monoamine release. The prodrug design requires GI absorption and enzymatic conversion—snorting or injection bypasses intended release and increases overdose and abuse risk per labeling.

Sympathomimetic cardiovascular effects (increased blood pressure and heart rate) and CNS stimulation explain the nursing focus on vitals, sleep, appetite, and controlled-substance safeguards.

Dosing follows Vyvanse prescribing information. Take once daily in the morning with or without food; avoid afternoon doses because of insomnia risk. Assess cardiac disease, family history of sudden death, and tics before initiating therapy.

ADHD (adults and pediatric patients ≥6 years)

• Starting dose: 30 mg once daily in the morning
• Titration: increase by 10 mg or 20 mg at approximately weekly intervals
• Maximum: 70 mg once daily

Binge eating disorder (adults)

• Starting dose: 30 mg once daily
• Titration: increase by 20 mg at approximately weekly intervals toward target 50–70 mg once daily
• Maximum: 70 mg once daily; discontinue if binge eating does not improve

Renal impairment

• Severe renal impairment (GFR 15 to <30 mL/min/1.73 m²): maximum 50 mg once daily
• End-stage renal disease (GFR <15): maximum 30 mg once daily

Hepatic dose adjustment: Not specified in the reviewed prescribing information—follow prescriber and pharmacy guidance.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Assess risk for abuse, misuse, and addiction before prescribing and throughout therapy
• Baseline heart rate, blood pressure, and orthostatic blood pressure when ordered
• Cardiac history: structural abnormalities, cardiomyopathy, serious arrhythmia, coronary artery disease
• Screen for tics or Tourette syndrome; evaluate bipolar risk factors
• Review MAOI use within 14 days and serotonergic agents (e.g., sertraline, triptans) and CYP2D6 inhibitors
• Verify allergy to amphetamine products; complete medication reconciliation for duplicate stimulants

Contraindications

• Known hypersensitivity to amphetamine products or Vyvanse components (anaphylaxis, Stevens-Johnson syndrome, angioedema reported)
• MAOI use within 14 days of stopping (including linezolid or IV methylene blue)—hypertensive crisis risk

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral once daily in the morning. Follow medication administration rights and Schedule II documentation.

• Capsules: swallow whole; may open and dissolve contents in water, yogurt, or orange juice and consume immediately; do not store dissolved mixture
• Chewable tablets: chew thoroughly before swallowing
• Do not divide capsule contents for partial doses unless prescriber and pharmacy direct a specific method
• Secure storage in a locked location; never leave unsecured doses accessible to others

• Improved attention, reduced impulsivity, and better functional performance in ADHD
• Reduction in binge days in adults with BED when appropriately indicated
• Acceptable BP and pulse within prescriber-defined limits after titration
• Tolerable appetite and sleep effects; mild decreased appetite may occur
• No evidence of misuse, diversion, or escalating dose without orders

Escalate immediately for cardiovascular, neurologic, serotonin, or substance-misuse concerns.

• Severe chest pain, syncope, unexplained dyspnea, or sustained tachycardia at rest
• Hypertensive crisis or serotonin syndrome symptoms (agitation, hyperthermia, tremor, confusion) especially with MAOIs or serotonergic stacks
• New psychosis, mania, hallucinations, or severe agitation
• Peripheral vasculopathy (Raynaud phenomenon, digital ulceration), seizures, or priapism
• Suspected overdose, snorting/injection misuse, or diversion—activate poison control/toxicology per protocol

Most common adverse reactions (incidence ≥5% and at least twice placebo) in ADHD trials included decreased appetite, insomnia, dry mouth, anxiety, decreased weight, diarrhea, dizziness, irritability, nausea, upper abdominal pain, and vomiting per labeling. In adults with BED, common reactions included dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery, and anxiety.

↔On a small screen, swipe or scroll sideways to see the full table.

Overdose of CNS stimulants may cause tachyarrhythmias, hypertension or hypotension, psychomotor agitation, confusion, hallucinations, serotonin syndrome, seizures, hyperthermia (>104°F), and rhabdomyolysis per Vyvanse overdosage labeling.

Antidote

No specific antidote is listed in the reviewed prescribing information. Management is supportive. Lisdexamfetamine and dextroamphetamine are not dialyzable.

• Contact local poison control or toxicology services per facility protocol and local emergency guidance
• Consider possibility of multiple drug ingestion; monitor airway, circulation, temperature, and cardiac rhythm
• Document amount, time, and route (especially if non-oral misuse suspected)

• Vyvanse vs other stimulants (mixed amphetamine salts, methylphenidate products)—verify generic name; do not assume milligram equivalence across agents
• Lisdexamfetamine vs dexmethylphenidate—different molecules, dosing, and schedules; independent double-check
• Capsule vs chewable tablet at same strength—confirm formulation on MAR
• 70 mg vs 7 mg or 30 mg vs 300 mg transcription errors—barcode scan and pharmacist verification on titration
• Duplicate stimulant orders at admission—reconcile home, ER, and psychiatry lists

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Blood pressure and pulse at baseline, after each dose increase, and periodically during maintenance
• Weight, height (pediatrics), appetite, and sleep pattern
• ADHD or BED symptom response and functional outcomes
• Signs of abuse, misuse, addiction, or diversion; pill counts and refill timing
• Psychiatric symptoms, tics, and digital changes suggesting vasculopathy
• Renal function when dosing in impairment

Document

• Strength, formulation (capsule/chewable), morning administration time, and titration plan
• Vital sign trends and prescriber notifications for out-of-range values
• Abuse-risk assessment, patient education on storage, and controlled-substance accountability

• Take once daily in the morning exactly as prescribed—do not share medication (Schedule II abuse risk)
• Store in a secure, preferably locked location; dispose of unused medication per local take-back programs
• Report chest pain, fainting, palpitations, severe headache, or new psychiatric symptoms promptly
• Do not start MAOIs or St. John’s wort without prescriber guidance; tell clinicians about all cold medicines
• Never crush, snort, or inject capsules—overdose and death risk increases with misuse
• Contact local poison control or emergency services per facility protocol for suspected overdose

Do not give and contact the prescriber or pharmacist when:

Hold parameters may vary by institutional policy; align with psychiatry, cardiology, and pharmacy when comorbidities exist.

Rehearse NCLEX-style clinical judgment practice for lisdexamfetamine using the tabbed outpatient case (MAR · Labs · Vitals · Nursing notes), then priority action, cue recognition SATA, trend SATA, matrix urgency sorting for abuse and cardiovascular risk, clinical MCQ, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

Unfolding case. Jordan is a 19-year-old university student with ADHD starting Vyvanse 50 mg every morning—day 7 at this dose after a weekly increase from 30 mg. He has treated hypertension, no structural cardiac disease documented, and reports a friend asked to “borrow a capsule for studying.” Psychiatry wants nursing to monitor cardiovascular parameters and Schedule II safety at an outpatient visit.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.